Panacea Biotec Management
Management criteria checks 4/4
Panacea Biotec's CEO is Rajesh Jain, appointed in Feb 2002, has a tenure of 23.58 years. total yearly compensation is ₹9.01M, comprised of 66.6% salary and 33.4% bonuses, including company stock and options. directly owns 49.33% of the company’s shares, worth ₹12.26B. The average tenure of the management team and the board of directors is 10.3 years and 9.4 years respectively.
Key information
Rajesh Jain
Chief executive officer
₹9.0m
Total compensation
| CEO salary percentage | 66.59% |
| CEO tenure | 23.6yrs |
| CEO ownership | 49.3% |
| Management average tenure | 10.3yrs |
| Board average tenure | 9.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | ₹115m |
| Mar 31 2025 | n/a | n/a | -₹84m |
| Dec 31 2024 | n/a | n/a | -₹79m |
| Sep 30 2024 | n/a | n/a | -₹147m |
| Jun 30 2024 | n/a | n/a | -₹279m |
| Mar 31 2024 | ₹9m | ₹6m | -₹12m |
| Dec 31 2023 | n/a | n/a | -₹117m |
| Sep 30 2023 | n/a | n/a | ₹99m |
| Jun 30 2023 | n/a | n/a | ₹334m |
| Mar 31 2023 | ₹8m | ₹6m | -₹332m |
| Dec 31 2022 | n/a | n/a | ₹12b |
| Sep 30 2022 | n/a | n/a | ₹11b |
| Jun 30 2022 | n/a | n/a | ₹11b |
| Mar 31 2022 | ₹8m | ₹6m | ₹11b |
| Dec 31 2021 | n/a | n/a | -₹2b |
| Sep 30 2021 | n/a | n/a | -₹2b |
| Jun 30 2021 | n/a | n/a | -₹2b |
| Mar 31 2021 | ₹7m | ₹6m | -₹1b |
| Dec 31 2020 | n/a | n/a | -₹2b |
| Sep 30 2020 | n/a | n/a | -₹1b |
| Jun 30 2020 | n/a | n/a | -₹2b |
| Mar 31 2020 | ₹8m | ₹6m | -₹2b |
| Dec 31 2019 | n/a | n/a | ₹653m |
| Sep 30 2019 | n/a | n/a | ₹715m |
| Jun 30 2019 | n/a | n/a | ₹482m |
| Mar 31 2019 | ₹7m | ₹6m | ₹410m |
Compensation vs Market: Rajesh's total compensation ($USD102.21K) is below average for companies of similar size in the Indian market ($USD186.96K).
Compensation vs Earnings: Rajesh's compensation has been consistent with company performance over the past year.
CEO
Rajesh Jain (61 yo)
Dr. Rajesh Jain, Ph D has been Managing Director at Panacea Biotec Limited since March 12, 2018 and serves as its Whole-Time Director and serves as its Chairman of the Board at Panacea Biotec Limited since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & MD | 23.6yrs | ₹9.01m | 49.33% ₹ 12.3b | |
| Joint MD & Executive Director | 23.6yrs | ₹8.37m | 15.27% ₹ 3.8b | |
| CFO & Head of Information Technology | 10.3yrs | ₹6.43m | no data | |
| Chief Scientific Officer | no data | ₹6.53m | no data | |
| Group CFO | 10.3yrs | ₹8.43m | no data | |
| Whole-Time Director | 1.3yrs | ₹3.03m | no data | |
| Chief Operating Officer | 5.8yrs | no data | no data | |
| General Manager of Accounts & Taxation | no data | no data | no data | |
| Chief Information Officer | no data | no data | 0% ₹ 0 | |
| Senior Vice President of Sales | no data | ₹5.61m | no data | |
| Senior Vice President of Human Resources | no data | ₹6.10m | no data | |
| Senior Vice President of Pharma Research & Pharma Regulatory Affairs | 5.8yrs | no data | no data |
Experienced Management: 531349's management team is seasoned and experienced (10.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & MD | 40.8yrs | ₹9.01m | 49.33% ₹ 12.3b | |
| Joint MD & Executive Director | 40.8yrs | ₹8.37m | 15.27% ₹ 3.8b | |
| Whole-Time Director | 9.4yrs | ₹3.03m | no data | |
| Non-Executive Independent Director | 9.4yrs | ₹20.00k | no data | |
| Non-Executive Independent Director | 1.6yrs | no data | no data |
Experienced Board: 531349's board of directors are considered experienced (9.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/06 20:10 |
| End of Day Share Price | 2025/09/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Panacea Biotec Limited is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Amit Gupta | Batlivala & Karani Securities India Pvt. Ltd. |
| Arvind Bothra | BofA Global Research |